Birth Tissue Products Market Size, Share, and COVID-19 Impact Analysis, By Tissue Type (Placenta, Amniotic Fluid, and Umbilical Cord), By Application (Ophthalmology, Oncology, Wound Healing, Orthopedics, and Others), By End-User (Hospital & ASCs, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Birth tissue products refers to products that are made from the donated human tissue after birth to treat a variety of conditions including musculoskeletal, cardiovascular, and others. They are a natural source of proteins and cells that can be used to regenerate the cells and tissues. The increasing awareness about these birth tissue products among the population is raising the adoption of these devices which is further augmenting the demand for novel products, thereby leading the key players to focus on receiving approval for their new and advanced products for the treatment of varying conditions.

• For instance, in January 2021, Organogenesis Inc., received regenerative medicine advanced therapy (RMAT) designation from U.S. FDA approval for their product ReNu, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis (OA).

Moreover, increasing technological advancements such as intgegration of 3D bioprinting technology, induced pluripotent stem-cell technology, and others is leading to the rising adoption of birth tissue products. The rising rate of replacement and reconstructive operative procedures among the patient population is to accelerate the growth of the market. The stem cells from a donated birth tissue can be modified to specific organs and tissues to treat painful, non-healing wounds, burns, and others. 

• In November 2022, according to an American Joint Replacement Registry, reported approximately 2.8 million hip and knee replacement procedures in the U.S.

Additionally, increasing prevalence of certain diseases such as cardiovascular diseases, musculoskeletal disorders, and others is contributing to the increasing demand of birth tissue products among the healthcare providers. This is leading the focus of the governmental and non-governmental organizations to promote these products and their safety among the patients which is likely to pose a positive impact on the growth of the market.

• In February 2022, Government of India announced the funding for research institutions such as Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST) with an aim to promote stem-cell therapy among the population.

Impact of COVID-19 on Birth Tissue Products Market 

The COVID-19 pandemic negatively impacted the birth tissue products market. The health and safety measures put in place to protect against the spread of the virus caused a decline in elective procedures such as C-section, which is a major source for birth tissues. This along with, travel restrictions to hospitals decreased the birth rate during the pandemic which severely impacted the availability of birth tissue products among the patient population and posed a negative impact on the market.

• For instance, according to an article published by Proceedings of the National Academy of Sciences (PNAS), it was reported that there was 3.8% drop in birth rate in 2020 with an  accelerating rate of decline at the end of 2020. This decreased rate impacted the availability of these birth tissues for the production of bith tissue products among population.

Furthermore, the pandemic resulted into a heavy disruption in supply chain which made difficult for industries and organizations to source and distribute these birth tissue products during the pandemic and decreased the demand for these birth tissue products among the patient population. 

Key Insights: 

• Technological Advancements in Birth Tissue Products.
• New Product launches, By Key Players.
• Key Industry developments- Partnerships, Mergers, and Acquisitions.
• Impact of COVID-19 on Birth Tissue Products Market.

Analysis by Tissue Type:

Based on the tissue type, the market is bifurcated into placenta, umbilical cord, and amniotic fluid. Amongst these, the umbilical cord is anticipated to hold a dominant position in the birth tissue products market. Umbilical cord is a rich source of stem cells which makes it useful as regenerative medicine. The other properties such as its renewability, ease of collection, and others are some of the major factors contributing to the dominance of the segment. Also, umbilical cord can be used to treat neurological disorders such as Alzheimer’s, Parkinson, and others which is enabling the key players to launch various products with umbilical cord in the market, thereby contributing to the growth of the segment.

• For instance, in January 2020, Royal Biologics launched Cryo-Cord, the first non-DMSO viable umbilical cord graft to expand regenerative healing for a wide variety of wounf types across the orthopedics segment.

On the other hand, amniotic fluid is anticipated to register a considerable growth. This is attributed to its potential use in wound healing, bone healing, burn and scar treatment, ophthalmology, and neurology. Therefore, rising awareness about the advantages of amniotic fluid is growing the demand for amniotic fluid products among healthcare providers, further leading the focus of key players on research and development activities to introduce technologically advanced products in the market.    

Regional Analysis: 

To gain extensive insights into the market, Download for Customization

North America market holds the largest share in the market due to increasing prevalence of chronic ailments in this region. Rising prevalence of this condition in the region is further increasing the replacement and reconstructive procedures among patients. The increasing demand for birth tissue products which is leading the regulatory bodies to stringently focus on the approval procedure in order to increase the availability of these products in the market. Increasing availability of birth tissue products is expected to cater the increasing demand of replacement and reconstructive procedures among patients which is anticipated to fuel the market.  

• For instance, in October 2022, according to a news published by Centers for Disease Control & Prevention, it was reported that about 20.1 million adults aged 20 and older are suffering with cardiovascular diseases in the U.S.

On the other hand, Europe is anticipated to register a considerable CAGR attributed to the rising awareness about birth tissue products among the patient population, further increasing the adoption of these products in the market. The rising awareness regarding the benefits of these products is enabling the key players to expand their product portfolio for regenerative medicine which is anticipated to positively impact the growth of the region in the market.

Key Players: 

The report will include the profiles of key players such as BioTissue, Mesoblast Ltd., PREDICTIVE BIOTECH, Integra LifeSciences, Cryolife, Inc., MTF Biologics, AlloSource, and others.

Segmentation: 

Key Industry Developments:

• October 2022: Sysmex and JCR Pharmaceuticals announced a joint venture in the field of regenerative medicine and cell therapy with an aim to expand their research & development activities for regenerative medicine products using stem cells.
• January 2021: Integra LifeSciences acquired ACell, Inc., with an aim to expand their complex wound management potfolio globally.